Drugs / HS-10376
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05435274 | Sep 2021 → Oct 2024 | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10376 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435274 ↗ |
| Action | Inhibit | “HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20 insertion mutation.” NCT05435274 ↗ |
| Modality | Small molecule | “HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20 insertion mutation.” NCT05435274 ↗ |
| Route | Oral | “HS-10376 will be administered orally once daily in a continuous regimen” NCT05435274 ↗ |
| Target | EGFR | “HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20 insertion mutation.” NCT05435274 ↗ |